612P Pembrolizumab (pembro) plus olaparib in patients with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Update of KEYNOTE-365 cohort A with a minimum of 11 months of follow-up for all patients
Year: 2021
Type: article
Source: Annals of Oncology
Institutions: University of Washington, Institut Català d'Oncologia, Institut Paoli-Calmettes, Auckland City Hospital, Centre Eugène Marquis, Hospital General Universitario Gregorio Marañón, Hôpital Européen Georges-Pompidou, Institut Gustave Roussy, Universitätsklinikum des Saarlandes, Urology Cancer Center and GU Research Network, Vall d'Hebron Hospital Universitari, Cross Cancer Institute, Paracelsus Medizinische Privatuniversität, Westmead Hospital, Macquarie University, University of Wollongong, Merck & Co., Inc., Rahway, NJ, USA (United States), Royal Marsden NHS Foundation Trust, Royal Marsden Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W3203319272